Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 34Neoplasms 10Prostatic Neoplasms 6Neoplasm Metastasis 6Carcinoma, Ovarian Epithelial 5Unspecified Adult Solid Tumor, Protocol Specific 4Ovarian Neoplasms 4Lymphoma, Mantle-Cell 4Lymphoma, Follicular 4Carcinoma, Non-Small-Cell Lung 4Breast Neoplasms, Male 4Stomach Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Lymphoma, Non-Hodgkin 3Lymphoma, Large-Cell, Anaplastic 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma, B-Cell, Marginal Zone 3Lymphoma 3Leukemia, Lymphocytic, Chronic, B-Cell 3Carcinoma, Renal Cell 3Burkitt Lymphoma 3Wilms Tumor 2Testicular Neoplasms 2Teratoma 2Squamous Cell Carcinoma of Head and Neck 2Sarcoma 2Salivary Gland Neoplasms 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Pancreatic Neoplasms 2Osteosarcoma 2

Interventions

ixabepilone 1ST 1481 1Paclitaxel 1Fulvestrant 1Axitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Solid Malignancies × ixabepilone × Clear all
NCT00162136 2020-11-02

Clinical Study of Ixabepilone Administered as a 24 Hour Infusion in Patients With Solid Malignancies.

R-Pharm

Phase 1 Completed
35 enrolled 17 charts

Solid Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡